Novan

    OverviewSuggest Edit

    Novan is a clinical-stage biotechnology company focused on leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. It develops NITRICIL technology that allows the control of the level of nitric oxide storage, the rate of release, and the molecule size for targeted delivery.
    TypePrivate
    Founded2008
    HQNC, US
    Websitenovan.com
    Employee Ratings2.7

    Latest Updates

    Employees (est.) (Apr 2022)47(+3%)
    Share Price (May 2022)$2.3(-10%)
    Cybersecurity ratingAMore
    Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
    Banner background

    Key People/Management at Novan

    Carri Geer

    Carri Geer

    Senior Vice President and Chief Technology Officer
    John M. Gay

    John M. Gay

    Chief Financial Officer
    Kent Geer

    Kent Geer

    Lead Independent Director
    Paula Brown Stafford

    Paula Brown Stafford

    President and Chief Executive Officer, Director
    Brian Johnson

    Brian Johnson

    Chief Commercial Officer
    Tomoko Maeda-chubachi

    Tomoko Maeda-chubachi

    Chief Medical Officer
    Show more

    Novan Office Locations

    Novan has an office in Durham
    Durham, NC, US
    4020 Stirrup Creek Dr #110
    Show all (2)

    Novan Financials and Metrics

    Summary Metrics

    Founding Date

    2008

    Novan Cybersecurity Score

    Cybersecurity ratingPremium dataset

    A

    95/100

    SecurityScorecard logo

    Novan Online and Social Media Presence

    Embed Graph

    Novan News and Updates

    Novan to Report First Quarter 2022 Financial Results on May 16, 2022

    DURHAM, N.C., May 06, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2022 financial results on Monday, May 16th. Novan management will host a conference call and live audio webcast to discuss the operational and…

    Novan Announces Late-Breaking Abstract Accepted for Presentation at American Academy of Dermatology’s (AAD) 2022 Annual Meeting

    DURHAM, N.C., March 24, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that data from its pivotal Phase 3 study of berdazimer gel 10.3% (SB206) for the treatment of molluscum contagiosum was selected for an oral presentation at a late-breaker sessio…

    Novan, Inc. to Present at Two Upcoming Investor Conferences

    DURHAM, N.C., March 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will be presenting at two upcoming investor conferences.

    Novan Acquires EPI Health, a Specialty Dermatology Company

    Acquisition Represents Forward Integration as a Commercial Organization Acquisition Represents Forward Integration as a Commercial Organization

    Novan Reports Full Year 2021 Financial Results and Provides Corporate Update

    – First New Drug Application (NDA) submission targeted in Q4 2022 for lead program SB206 (berdazimer gel 10.3%) for molluscum contagiosum –

    Novan to Report Full Year 2021 Financial Results on February 22, 2022

    DURHAM, N.C., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its full year 2021 financial results on Tuesday, February 22nd. Novan management will host a conference call and live audio webcast to discuss the operational …
    Show more

    Novan Blogs

    Novan to Participate in the Virtual Investor Innovation in Dermatology Spotlight Event

    Live moderated video webcast with members of the Novan management team on Tuesday, April 26th at 2:00 PM ET DURHAM, N.C., April 20, 2022 — Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced it will participate in the Virtual Investor Innovation in Dermatology Spotlight event on T…

    Novan Announces Closing of $40 Million Public Offering of Common Stock

    DURHAM, N.C., June 21, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company" or "Novan") (NASDAQ:NOVN) today announced the closing of the Company's previously announced underwritten public offering (the “Offering”) of 3,636,364 shares of common stock at a public offering price of $11.00 per share.

    Novan Announces Proposed Public Offering of Common Stock

    DURHAM, N.C., June 16, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company” or “Novan”) (NASDAQ: NOVN) today announced a proposed underwritten public offering of its common stock (the “Offering”). All shares to be sold in the Offering will be sold by Novan.

    Novan Announces 1-for-10 Reverse Stock Split

    Novan Announces 1-for-10 Reverse Stock Split Content Import Tue, 05/25/2021 - 08:01 Novan Announces 1-for-10 Reverse Stock Split May 25, 2021 at 8:01 AM EDT This release is a backfill from a News Wire Press Releases …

    Novan Reports First Quarter 2021 Financial Results and Provides Corporate Update

    – Topline efficacy results for ongoing Phase 3 study evaluating SB206 as a treatment for molluscum on track for targeted readout before the end of Q2 2021 – – Preclinical program underway evaluating SB019 with berdazimer sodium as a potential intranasal therapy for COVID-19, with results targeted

    Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology

    Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology Content Import Thu, 04/22/2021 - 09:01 Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology April 22, 2021 at 9:01 AM EDT Thi…
    Show more

    Novan Frequently Asked Questions

    • When was Novan founded?

      Novan was founded in 2008.

    • Who are Novan key executives?

      Novan's key executives are Carri Geer, John M. Gay and Kent Geer.

    • How many employees does Novan have?

      Novan has 47 employees.

    • Who are Novan competitors?

      Competitors of Novan include BI/OND, HuaBio and Sinopia Biosciences.

    • Where are Novan offices?

      Novan has an office in Durham.

    • How many offices does Novan have?

      Novan has 2 offices.